Literature DB >> 24297891

MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Maartje G Huijbers1, Wei Zhang, Rinse Klooster, Erik H Niks, Matthew B Friese, Kirsten R Straasheijm, Peter E Thijssen, Hans Vrolijk, Jaap J Plomp, Pauline Vogels, Mario Losen, Silvère M Van der Maarel, Steven J Burden, Jan J Verschuuren.   

Abstract

Myasthenia gravis (MG) is a severely debilitating autoimmune disease that is due to a decrease in the efficiency of synaptic transmission at neuromuscular synapses. MG is caused by antibodies against postsynaptic proteins, including (i) acetylcholine receptors, the neurotransmitter receptor, (ii) muscle-specific kinase (MuSK), a receptor tyrosine kinase essential for the formation and maintenance of neuromuscular synapses, and (iii) low-density lipoprotein receptor-related protein 4 (Lrp4), which responds to neural Agrin by binding and stimulating MuSK. Passive transfer studies in mice have shown that IgG4 antibodies from MuSK MG patients cause disease without requiring complement or other immune components, suggesting that these MuSK antibodies cause disease by directly interfering with MuSK function. Here we show that pathogenic IgG4 antibodies to MuSK bind to a structural epitope in the first Ig-like domain of MuSK, prevent binding between MuSK and Lrp4, and inhibit Agrin-stimulated MuSK phosphorylation. In contrast, these IgG4 antibodies have no direct effect on MuSK dimerization or MuSK internalization. These results provide insight into the unique pathogenesis of MuSK MG and provide clues toward development of specific treatment options.

Entities:  

Keywords:  Dok7; Rapsyn; activation loop; insulin receptor; neuromuscular junction

Mesh:

Substances:

Year:  2013        PMID: 24297891      PMCID: PMC3870730          DOI: 10.1073/pnas.1313944110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.

Authors:  Shuuichi Mori; Sachiho Kubo; Takuyu Akiyoshi; Shigeru Yamada; Tsuyoshi Miyazaki; Harumi Hotta; Junzo Desaki; Masahiko Kishi; Tetsuro Konishi; Yuri Nishino; Atsuo Miyazawa; Naoki Maruyama; Kazuhiro Shigemoto
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

2.  Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L.

Authors:  Peter T Hallock; Chong-Feng Xu; Tae-Ju Park; Thomas A Neubert; Tom Curran; Steven J Burden
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

3.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.

Authors:  Alexandra Pevzner; Benedikt Schoser; Katja Peters; Nicoleta-Carmen Cosma; Andromachi Karakatsani; Berthold Schalke; Arthur Melms; Stephan Kröger
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

4.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

5.  Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.

Authors:  Jie Luo; Palmer Taylor; Mario Losen; Marc H de Baets; G Diane Shelton; Jon Lindstrom
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

6.  Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK).

Authors:  Wei Zhang; Anne-Sophie Coldefy; Stevan R Hubbard; Steven J Burden
Journal:  J Biol Chem       Date:  2011-10-03       Impact factor: 5.157

7.  Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.

Authors:  Arezou Khosroshahi; Donald B Bloch; Vikram Deshpande; John H Stone
Journal:  Arthritis Rheum       Date:  2010-06

8.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

9.  Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

Authors:  R N Cole; N Ghazanfari; S T Ngo; O L Gervásio; S W Reddel; W D Phillips
Journal:  J Physiol       Date:  2010-07-05       Impact factor: 5.182

10.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

View more
  72 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 3.  Mechanisms controlling neuromuscular junction stability.

Authors:  Evelyne Bloch-Gallego
Journal:  Cell Mol Life Sci       Date:  2014-10-31       Impact factor: 9.261

4.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

Review 5.  IgG4-associated cholangitis: a comprehensive review.

Authors:  Lowiek M Hubers; Lucas J Maillette de Buy Wenniger; Marieke E Doorenspleet; Paul L Klarenbeek; Joanne Verheij; Erik A Rauws; Thomas M van Gulik; Ronald P J Oude Elferink; Stan F J van de Graaf; Niek de Vries; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Authors:  Nazanin Ghazanfari; Marco Morsch; Stephen W Reddel; Simon X Liang; William D Phillips
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

Review 7.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

8.  Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4.

Authors:  Kai Zhao; Chengyong Shen; Lei Li; Haitao Wu; Guanglin Xing; Zhaoqi Dong; Hongyang Jing; Wenbing Chen; Hongsheng Zhang; Zhibing Tan; Jinxiu Pan; Lei Xiong; Hongsheng Wang; Wanpeng Cui; Xiang-Dong Sun; Shihua Li; Xinping Huang; Wen-Cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2018-08-31       Impact factor: 6.167

Review 9.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

10.  LRP4 is critical for neuromuscular junction maintenance.

Authors:  Arnab Barik; Yisheng Lu; Anupama Sathyamurthy; Andrew Bowman; Chengyong Shen; Lei Li; Wen-cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.